AR093585A1 - Composicion para liberacion inmediata y prolongada - Google Patents
Composicion para liberacion inmediata y prolongadaInfo
- Publication number
- AR093585A1 AR093585A1 ARP130104308A ARP130104308A AR093585A1 AR 093585 A1 AR093585 A1 AR 093585A1 AR P130104308 A ARP130104308 A AR P130104308A AR P130104308 A ARP130104308 A AR P130104308A AR 093585 A1 AR093585 A1 AR 093585A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- composition according
- active ingredient
- tolterodine
- inner layer
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 abstract 9
- 239000004480 active ingredient Substances 0.000 abstract 7
- 239000010410 layer Substances 0.000 abstract 5
- 239000011159 matrix material Substances 0.000 abstract 4
- 229960004045 tolterodine Drugs 0.000 abstract 4
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 abstract 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 4
- 238000013270 controlled release Methods 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 abstract 3
- 239000002160 alpha blocker Substances 0.000 abstract 2
- 230000001022 anti-muscarinic effect Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000007789 sealing Methods 0.000 abstract 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 abstract 1
- FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical group C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 abstract 1
- 229920001202 Inulin Polymers 0.000 abstract 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 abstract 1
- 240000007472 Leucaena leucocephala Species 0.000 abstract 1
- 229920002774 Maltodextrin Polymers 0.000 abstract 1
- 239000005913 Maltodextrin Substances 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- 239000011247 coating layer Substances 0.000 abstract 1
- 229960002845 desmopressin acetate Drugs 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 abstract 1
- 229940029339 inulin Drugs 0.000 abstract 1
- 229940035034 maltodextrin Drugs 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 abstract 1
- 235000010413 sodium alginate Nutrition 0.000 abstract 1
- 239000000661 sodium alginate Substances 0.000 abstract 1
- 229940005550 sodium alginate Drugs 0.000 abstract 1
- -1 swarm Polymers 0.000 abstract 1
- 229960002613 tamsulosin Drugs 0.000 abstract 1
- 229920003169 water-soluble polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3575DE2012 | 2012-11-21 | ||
| IN3947DE2012 | 2012-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR093585A1 true AR093585A1 (es) | 2015-06-10 |
Family
ID=49619947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130104308A AR093585A1 (es) | 2012-11-21 | 2013-11-21 | Composicion para liberacion inmediata y prolongada |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP2922525A1 (h) |
| JP (1) | JP2016500088A (h) |
| KR (1) | KR20150085826A (h) |
| CN (1) | CN104797240A (h) |
| AR (1) | AR093585A1 (h) |
| AU (1) | AU2013349682A1 (h) |
| BR (1) | BR112015011430A2 (h) |
| CA (1) | CA2891365A1 (h) |
| EA (1) | EA201590805A1 (h) |
| HK (1) | HK1213779A1 (h) |
| IL (1) | IL238648A0 (h) |
| IN (1) | IN2015DN03984A (h) |
| MX (1) | MX2015006399A (h) |
| PH (1) | PH12015501096A1 (h) |
| SG (2) | SG10201703388TA (h) |
| TW (1) | TW201422254A (h) |
| WO (1) | WO2014079922A1 (h) |
| ZA (1) | ZA201503603B (h) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2016001030A (es) | 2013-07-23 | 2016-10-07 | Allergan Inc | Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico. |
| KR20150144209A (ko) * | 2014-06-16 | 2015-12-24 | 훼링 비.브이. | 안정화된 데스모프레신 또는 이의 약학적으로 허용가능한 염을 함유 약학 조성물 |
| CN106999538A (zh) * | 2014-11-20 | 2017-08-01 | 阿勒根公司 | 包含去氨加压素与α‑肾上腺素能受体拮抗剂组合的方法和组合物 |
| EP3244881A4 (en) | 2015-01-12 | 2018-08-15 | Nano Pharmaceutical Laboratories LLC | Layered sustained-release microbeads and methods of making the same |
| EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| RU2018111400A (ru) * | 2015-09-01 | 2019-10-03 | УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Препарат пролонгированного, отсроченного и немедленного высвобождения, способ его получения и применения |
| EP3355864A4 (en) * | 2015-09-30 | 2019-05-22 | Wellesley Pharmaceuticals, LLC | COMPOSITION FOR REDUCING URINATION FREQUENCY, METHOD FOR THE PREPARATION AND USE THEREOF |
| EP3355877A4 (en) * | 2015-09-30 | 2019-05-15 | Wellesley Pharmaceuticals, LLC | COMPOSITION FOR REDUCING URINATION FREQUENCY, METHOD FOR THE PREPARATION AND USE THEREOF |
| TW201726114A (zh) * | 2015-11-23 | 2017-08-01 | 魏斯理製藥公司 | 降低排尿頻率之組成物、其製備方法、及其應用 |
| EP3389661A4 (en) * | 2015-12-18 | 2019-12-18 | Wellesley Pharmaceuticals, LLC | COMPOSITION FOR REDUCING THE FREQUENCY OF URINATION, METHOD FOR THE PRODUCTION AND USE THEREOF |
| JP7158284B2 (ja) | 2016-04-21 | 2022-10-21 | ヴァルキュリア アクチアボラグ | がんを前処置するための組成物および方法 |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| JP7042275B2 (ja) * | 2017-01-11 | 2022-03-25 | フェリング・ベー・フェー | 速崩壊性医薬組成物 |
| WO2019039836A2 (ko) * | 2017-08-22 | 2019-02-28 | 아주대학교산학협력단 | 퇴행성 신경질환 치료용 복합 제형 조성물 |
| US12389928B1 (en) * | 2024-10-25 | 2025-08-19 | Mccormick & Company, Inc. | Flavor-changing product |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4052997A (en) | 1996-07-19 | 1998-02-10 | Clarke-Garegg, Margaret A. | Levan derivatives, their preparation, composition and applications including medical and food applications |
| SE9803871D0 (sv) | 1998-11-11 | 1998-11-11 | Pharmacia & Upjohn Ab | Therapeutic method and formulation |
| GB9908014D0 (en) | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| EP1064938A1 (en) * | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Pharmaceutical dosage forms for controlled release producing at least a timed pulse |
| US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
| GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
| DE60307082D1 (de) * | 2002-05-07 | 2006-09-07 | Ferring Bv | In der mundhöhle dispergierbare phamarzeutische zusammensetzung mit desmopressin |
| US8012505B2 (en) | 2003-02-28 | 2011-09-06 | Alk-Abello A/S | Dosage form having a saccharide matrix |
| CN100366294C (zh) | 2004-04-30 | 2008-02-06 | 量子高科（北京）研究院有限公司 | 一种口腔速溶制剂及其生产方法 |
| EP1629834A1 (en) | 2004-08-27 | 2006-03-01 | KRKA, D.D., Novo Mesto | Sustained release pharmaceutical composition of tolterodine |
| WO2007029087A2 (en) | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Controlled release multiple unit formulations |
| US20090192228A1 (en) | 2008-01-28 | 2009-07-30 | Actavis Group Ptc Ehf | Controlled-Release Tolterodine Compositions and Methods |
| CN102245171A (zh) * | 2008-11-10 | 2011-11-16 | 株式会社爱茉莉太平洋 | 缓释微粒及其制备方法 |
| CA2769760A1 (en) * | 2009-07-31 | 2011-02-03 | Ranbaxy Laboratories Limited | Multi-layered, multiple unit pharmaceutical compositions |
| ES2643087T3 (es) | 2010-03-29 | 2017-11-21 | Ferring B.V. | Composición farmacéutica de disolución rápida |
| JO3112B1 (ar) * | 2010-03-29 | 2017-09-20 | Ferring Bv | تركيبة دوائية سريعة التحلل |
| MX356601B (es) * | 2010-03-30 | 2018-05-29 | Productos Maver S A De C V | Combinación farmacéutica con efecto antimigrañoso, en presentación sólida de liberación diferenciada. |
| US20120135050A1 (en) * | 2010-07-08 | 2012-05-31 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
-
2013
- 2013-11-11 TW TW102140886A patent/TW201422254A/zh unknown
- 2013-11-21 EP EP13792703.4A patent/EP2922525A1/en not_active Withdrawn
- 2013-11-21 EA EA201590805A patent/EA201590805A1/ru unknown
- 2013-11-21 WO PCT/EP2013/074373 patent/WO2014079922A1/en active Application Filing
- 2013-11-21 IN IN3984DEN2015 patent/IN2015DN03984A/en unknown
- 2013-11-21 SG SG10201703388TA patent/SG10201703388TA/en unknown
- 2013-11-21 KR KR1020157015219A patent/KR20150085826A/ko not_active Withdrawn
- 2013-11-21 HK HK16101745.8A patent/HK1213779A1/zh unknown
- 2013-11-21 CN CN201380060349.8A patent/CN104797240A/zh active Pending
- 2013-11-21 AU AU2013349682A patent/AU2013349682A1/en not_active Abandoned
- 2013-11-21 SG SG11201503913TA patent/SG11201503913TA/en unknown
- 2013-11-21 CA CA2891365A patent/CA2891365A1/en not_active Abandoned
- 2013-11-21 MX MX2015006399A patent/MX2015006399A/es unknown
- 2013-11-21 AR ARP130104308A patent/AR093585A1/es unknown
- 2013-11-21 JP JP2015543424A patent/JP2016500088A/ja active Pending
- 2013-11-21 BR BR112015011430A patent/BR112015011430A2/pt not_active Application Discontinuation
-
2015
- 2015-05-05 IL IL238648A patent/IL238648A0/en unknown
- 2015-05-15 PH PH12015501096A patent/PH12015501096A1/en unknown
- 2015-05-21 ZA ZA2015/03603A patent/ZA201503603B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IN2015DN03984A (h) | 2015-10-02 |
| SG10201703388TA (en) | 2017-05-30 |
| BR112015011430A2 (pt) | 2017-07-11 |
| IL238648A0 (en) | 2015-06-30 |
| HK1213779A1 (zh) | 2016-07-15 |
| PH12015501096A1 (en) | 2015-07-27 |
| CN104797240A (zh) | 2015-07-22 |
| WO2014079922A1 (en) | 2014-05-30 |
| SG11201503913TA (en) | 2015-06-29 |
| JP2016500088A (ja) | 2016-01-07 |
| AU2013349682A1 (en) | 2015-06-04 |
| EA201590805A1 (ru) | 2015-11-30 |
| MX2015006399A (es) | 2015-07-21 |
| ZA201503603B (en) | 2016-01-27 |
| EP2922525A1 (en) | 2015-09-30 |
| TW201422254A (zh) | 2014-06-16 |
| KR20150085826A (ko) | 2015-07-24 |
| CA2891365A1 (en) | 2014-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR093585A1 (es) | Composicion para liberacion inmediata y prolongada | |
| PE20161373A1 (es) | Composiciones de liberacion retardada de linaclotida | |
| AR122580A2 (es) | Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales | |
| HRP20250181T1 (hr) | Spojevi i postupci za ciljanu razgradnju receptora androgena | |
| AR080735A1 (es) | Una composicion farmaceutica de disolucion rapida | |
| AR090898A1 (es) | Una formulacion de farmaco de liberacion retardada | |
| AR104984A1 (es) | Compuestos selectivos para pyy y sus usos | |
| JP2016518337A5 (h) | ||
| JP2016500088A5 (h) | ||
| MX366968B (es) | Molecula de union al antigeno que induce la inmunorespuesta al antigeno objetivo. | |
| MX2018014906A (es) | Composiciones farmaceuticas nasales con un excipiente poroso. | |
| BR112017008993A2 (pt) | métodos e composições especificamente para o tratamento de transtorno de déficit de atenção | |
| AR088232A1 (es) | Composiciones farmaceuticas | |
| AR080736A1 (es) | Composicion farmaceutica de disolucion rapida, usualmente bucodispersable, y proceso para prepararla | |
| PE20141539A1 (es) | Una nueva composicion terapeutica que contiene apomorfina como principio activo | |
| JP2013523676A5 (h) | ||
| AR093402A1 (es) | Producto de comicronizacion que comprende acetato de ulipristal | |
| AR092356A1 (es) | Formulacion compuesta para administracion oral que comprende metformina y rosuvastatina y metodo de preparacion de la formulacion | |
| CL2012003341A1 (es) | Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades. | |
| CL2016002318A1 (es) | Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits. | |
| CL2013003744A1 (es) | Compuestos derivados de 2-fenil-n-(piridin-hidroximetil)ciclopropanocarboxamida, moduladores alostéricos positivos (pams) del receptor nicotínico de acetilcolina alfa7; composición farmacéutica; y uso para el tratamiento de una enfermedad seleccionada entre psicosis, esquizofrenia, trastornos cognitivos, entre otros. | |
| PE20151300A1 (es) | Composicion antifungica topica para el tratamiento de onicomicosis | |
| MX2019004938A (es) | Cápsula compleja que contiene esomeprazol y método de preparación de esta. | |
| EP2939663A4 (en) | MELT EXTRUDED PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE AND MEDICAMENT FOR ORAL ADMINISTRATION THEREWITH | |
| FI3831385T3 (fi) | Pirlindolienantiomeerien mandelaattisuoloja käytettäviksi lääkinnässä |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |